Chronic Lymphocytic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Lymphocytic Leukemia stocks.

Chronic Lymphocytic Leukemia Stocks Recent News

Date Stock Title
May 17 BIIB Ionis, Biogen Down on Ending Development of ALS Drug
May 17 LGND Ionis, Biogen Down on Ending Development of ALS Drug
May 17 TEVA Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
May 16 BIIB Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16 LGND Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
May 16 LGND Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
May 16 BIIB Biogen and Ionis drop ALS candidate after trial setback
May 16 BIIB Biogen, Ionis shelve ALS drug following study failure
May 16 BIIB REFILE-UPDATE 2-Biogen, Ionis to discontinue development of experimental ALS drug
May 16 BIIB Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 BIIB Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16 LGND Insider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...
May 15 BIIB Eisai projects major growth for Alzheimer's therapy Leqembi
May 15 BIIB Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
May 15 EBS Walgreens launches its own opioid reversal therapy for OTC use
May 15 LGND FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
May 15 BIIB Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15 GMAB Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
May 15 BIIB Eisai sets new revenue target for Alzheimer’s drug Leqembi
May 15 TEVA Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

Browse All Tags